Research ArticleNeurology

TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study

Donatienne Van Weehaeghe, Evelien Van Schoor, Joke De Vocht, Michel Koole, Bala Attili, Sofie Celen, Lieven Declercq, Dietmar R. Thal, Philip Van Damme, Guy Bormans and Koen Van Laere
Journal of Nuclear Medicine April 2020, 61 (4) 604-607; DOI: https://doi.org/10.2967/jnumed.119.231985

Abstract

Neuroinflammation is important in amyotrophic lateral sclerosis (ALS). The P2X7 receptor (P2X7R) is a promising target for neuroinflammation. The objective of this study was to compare 18F-DPA714, a second-generation translocator protein tracer, with 11C-JNJ717, a novel P2X7R tracer, in vitro and in vivo in ALS. Methods: For the in vitro portion of the study, autoradiography with 18F-DPA714 and 11C-JNJ717 was performed on human ALS brain sections in comparison to immunofluorescence with Iba1 and GFAP. For the in vivo portion, 3 male patients with early-stage ALS (59.3 ± 7.2 y old) and 6 healthy volunteers (48.2 ± 16.5 y old, 2 men and 4 women) underwent dynamic PET/MR scanning with 18F-DPA714 and 11C-JNJ717. Volume-of-distribution images were calculated using Logan plots and analyzed on a volume-of-interest basis. Results: Autoradiography showed no difference in 11C-JNJ717 binding but did show increased 18F-DPA714 binding in the motor cortex correlating with Iba1 expression (glial cells). Similar findings were observed in vivo, with a 13% increase in 18F-DPA714 binding in the motor cortex. Conclusion: In symptomatic ALS patients, 18F-DPA714 showed increased signal whereas 11C-JNJ717 was not elevated.

Glial activation is important in amyotrophic lateral sclerosis (ALS) (1–3). Measurement may be of value for patient selection and assessment of therapy effectiveness. Until now, the most widely used PET target to study glial activation has been the translocator protein (TSPO). Several ALS studies demonstrated increased glial activation in motor and premotor regions, temporal cortex, pons, thalamus, and corticospinal tract (4–6). However, TSPO imaging has some drawbacks: relatively low signal-to-noise ratio, endothelial binding (7), and the need for genotyping before scanning (8). Therefore, other neuroinflammation targets have been investigated, such as the membrane P2X7 receptor (P2X7R). Activation of this receptor induces NLPR3 inflammasome formation and releases proinflammatory cytokines and reactive oxygen species. Recently, we have developed 11C-JNJ717, a P2X7R radioligand with a nanomolar affinity (1.6 nM), high specificity, and blood–brain barrier penetration. The tracer was validated in an animal model of neuroinflammation (9) and had a good test–retest variability in humans (10%–15%) (10).

The aim of this study was to perform a head-to-head comparison between the second-generation TSPO tracer 18F-labeled DPA714 (N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide) and 11C-labeled JNJ717 ([11C]JNJ54173717) in vitro using brain slices of ALS patients and in vivo in ALS patients and healthy volunteers (HVs).

MATERIALS AND METHODS

In Vitro

Snap-frozen 5-μm brain slices of 2 male ALS patients (mean age ± SD, 61.0 ± 10.0 y) were obtained using a cryotome. The occipital cortex (OC) was used as a control region because neuroinflammation in ALS is extensive in the motor cortex (MC) but negligible in the OC (4,6,11). Autoradiography was performed according to the protocol described by Ory et al. (9). Blocking percentages were calculated as (digital light units/mm2 in the presence of 20 μM blocker)/(digital light units/mm2 tracer only).

For immunohistochemistry, astrocytes and microglia were labeled with polyclonal rabbit anti–glial fibrillary acidic protein (GFAP) (1:300, Z0334, Dako; Agilent) and monoclonal mouse anti–ionized calcium binding adaptor molecule 1 (Iba1) (1:300, GT10312; Genetex). Afterward, the sections were incubated with goat antirabbit Cy5 (1:100, 111-175-144; Jackson Immunoresearch) and goat antimouse Cy3 (1:100, 115-165-003; Jackson Immunoresearch). The slides were mounted with ProLong Gold Antifade Mountant (Thermo Fisher Scientific). Whole-section images were acquired with a NanoZoomer S60 digital slide scanner (Hamamatsu Photonics) at ×20 magnification. The number of Iba1-positive and GFAP-positive cells was quantified per square millimeter in the area with highest density.

In Vivo

Six HVs (mean, 48.2 ± 16.5 y old; 2 men and 4 women, all medium-affinity binders) and 3 male ALS patients (59.3 ± 7.2 y old; 2 medium-affinity binders and 1 high-affinity binder) were included (Table 1). All subjects were genotyped for the rs6971 polymorphism and the 13 P2X7R exons (Supplemental Table 1; supplemental materials are available at http://jnm.snmjournals.org). The main exclusion criteria for HVs were low-affinity binding, abnormal findings on physical/neurologic/paraclinical examination, severe medical illness, and use of nonsteroidal antiphlogistics or corticosteroids (except for inhalation corticosteroids). ALS was diagnosed as probable or definite according to the Awaji-Shima or El Escorial criteria by an expert in neuromuscular disorders. The ALS patients had sporadic ALS disease and had been symptomatic for less than 1 y.

View this table:
TABLE 1

Subject Demographics

The study was performed in accordance with the World Medical Association Declaration of Helsinki and approved by the local University Ethics Committee. Written informed consent was obtained from all subjects before study participation.

Data were acquired on a Signa 3-T simultaneous PET/MR system (GE Healthcare) in list mode. All subjects underwent a 60-min 18F-DPA714 scan (251 ± 44 MBq) and a 70-min 11C-JNJ717 scan (142 ± 44 MBq). Multichannel segmentation (SPM, version 12) was performed to calculate subject-specific tissue probability maps (gray matter, white matter, and cerebrospinal fluid) using 2 imaging sequences of GE Healthcare: Bravo (a 3-dimensional volumetric T1-weighted sequence in the oblique plane, with an echo time of 3.2 ms, a repetition time of 8.5 ms, an inversion time of 450 ms, a flip angle of 12, a receiver bandwidth of 31.2, and 1 excitation) and Cube FLAIR (a 3-dimensional T2-weighted, fluid-attenuated inversion recovery sequence in the oblique plane, with an echo time of 136 ms, 1 echo, an echo train length of 190, a repetition time of 8,500 ms, an inversion time of 50 ms, a receiver bandwidth of 31.25, and 1 excitation).

PET data were reconstructed with ordered-subsets expectation maximization (28 subsets and 4 iterations) including time-of-flight information, resolution modeling, and in-plane gaussian postreconstruction smoothing (4 mm in full width half maximum). Every frame was rigidly coregistered to the averaged first 10 frames to correct for motion.

Arterial blood samples were taken from 0 (time of tracer injection) until the end of the scan. Radiometabolites in the plasma were analyzed to determine the percentage of intact tracer. Three exponential model curves were fitted to blood and plasma activity, whereas plasma radiometabolite data were fitted with a sigmoid function for 11C-JNJ717 and a Hill function for 18F-DPA714.

Spatial normalization (Montreal Neurological Institute template) was performed using both Bravo and 3-tissue-probability-map transformation (PMOD, version 3.7; PMOD Technologies). Voxel-based VT images were created using Logan graphical analysis (PMOD, version 3.7) with blood volume fixed to 5% and t* (equilibration time from which the plot is considered linear) to 31 and 36 min for 18F-DPA714 and 11C-JNJ717, respectively.

Region-based partial-volume correction (FreeSurfer, version 6.0; Laboratory for Computational Neuroimaging) was applied, and the atlas of Desikan et al. was used to delineate regions (12). After partial-volume correction, the ratio MC over OC was calculated to correct for genotype differences: Embedded Image

Nonparametric Wilcoxon-rank tests were performed in SPSS (version 25.0; IBM).

RESULTS

In Vitro

Autoradiography showed increased 18F-DPA714 uptake in the MC compared with the OC (ratio, 1.7) and full blocking (99.9%) (Fig. 1). No difference was observed in 11C-JNJ717 uptake between the 2 cortices with intermediate blocking (range, 58%–83%) with A740003, indicating a significant degree of nonspecific or off-target binding.

FIGURE 1.
FIGURE 1.

In vitro autoradiography experiments on MC and OC slices of 2 ALS patients. (A) Sections incubated with 18F-DPA714. (B) Sections incubated with 18F-DPA714 in presence of PK11195. (C) Sections incubated with 11C-JNJ717. (D) Sections incubated with 11C-JNJ717 in presence of A740003. (E) Immunohistochemistry results using Iba1 and GFAP. Scale bars represent 2.5 mm. WM = white matter; GM = gray matter.

Immunohistochemistry showed a 4-fold higher number of microglia (Iba1-positive cells) in the MC (69/mm2) than in the OC (17.5/mm2). In contrast, only a small increase in astrocytes (GFAP-positive cells) was observed in the MC (72/mm2), compared with the OC (57/mm2).

We observed regional colocalization between Iba1 staining and 18F-DPA714 uptake. No apparent colocalization between 18F-DPA714 and GFAP staining or between 11C-JNJ717 and Iba1/GFAP staining was detected visually.

In Vivo

In all ALS patients, we observed an increase in MC uptake for 18F-DPA714 but not for 11C-JNJ717 (Fig. 2). In patient 3, who presented with frontotemporal dysfunction, there was also an increase in frontal cortex uptake for 18F-DPA714. The ratio MC over OC without partial-volume correction was 1.03 ± 0.04 for ALS and 0.98 ± 0.04 for HV using 18F-DPA714 (P = 0.20) and 1.00 ± 0.06 for ALS and 0.97 ± 0.04 for HV using 11C-JNJ717 (P = 0.61). After partial-volume correction, the ratio was 1.10 ± 0.05 for ALS and 0.97 ± 0.08 for HV using 18F-DPA714 (P = 0.07) and 1.07 ± 0.09 for ALS and 1.04 ± 0.07 for HV using 11C-JNJ717 (P = 0.80). In this study, none of the subjects had the previously described P2X7R polymorphism (rs3751143) that may affect VT (10).

FIGURE 2.
FIGURE 2.

Overview of VT images (18F-DPA714 and 11C-JNJ717) of all ALS patients and average image of all HVs. Because of genotype effects for both tracers, different VT thresholds have been used. ALS patient 1 is 59-y-old man, ALS patient 2 is 50-y-old man, and ALS patient 3 is 68-y-old man (the patient with associated frontotemporal dysfunction).

DISCUSSION

Because neuroinflammation plays a crucial role in ALS, the availability of PET ligands that can visualize and quantify this process would be useful to guide patient selection in clinical trials and to allow in vivo therapeutic monitoring. In this study, we compared a second-generation TSPO radioligand, 18F-DPA714, with a promising novel neuroinflammation radioligand, 11C-JNJ717, as a proxy for P2X7R distribution in clinical ALS.

P2X7R involvement in ALS has been demonstrated preclinically in mouse models, in which blocking could be neuroprotective in early disease and neurotoxic in later phases, depending on the time of administration. Such a dual mode for P2X7R has been confirmed in microglia of SOD1-G93A mice, for which P2X7R activation releases both proinflammatory markers and antiinflammatory markers. It was hypothesized that P2X7R becomes important around the switch from the antiinflammatory to the proinflammatory phenotype (13). Also, clinically, increased P2X7R immunoreactivity has been observed in the spinal cord of ALS patients (14).

Our results show a visual increase in 18F-DPA714 binding in the MC in ALS patients on an individual level, whereas no regional increase in 11C-JNJ717 binding was observed. Additionally, in the patient with associated frontotemporal dysfunction, an increased 18F-DPA714 uptake in the frontal cortex was observed, concordant with the literature (15). The 18F-DPA714 VT ratio of MC to OC was 13% higher in ALS patients than in HVs, confirming our visual analysis. This increase was apparent both in vivo and in vitro and colocalized with microglial expression. Possibly, P2X7R might be upregulated in the brain only during early phases of the disease, concordant with preclinical results, as P2X7R is known to drive microglial activation (16). Moreover, in symptomatic ALS as studied in this report, the upregulation of P2X7R might be limited, necessitating the development of ligands with a greater specific-to-nondisplaceable ratio.

A limitation of the study is the lack of direct target (TSPO and P2X7R) immunohistochemistry. Nevertheless, the specificity of both tracers has been demonstrated in previous research (9,17–19). Future studies including direct target availability across the different disease stages are needed to validate our results and to investigate the presymptomatic and late symptomatic stages.

CONCLUSION

This study demonstrates that TSPO imaging—despite several drawbacks—outperforms P2X7R imaging in early symptomatic ALS patients.

DISCLOSURE

Koen Van Laere and Philip Van Damme are senior clinical investigators of the Fund for Scientific Research, Flanders, Belgium (FWO). Donatienne Van Weehaeghe (1179620N) and Evelien Van Schoor (1S46219N) are PhD fellows of the FWO. Philip Van Damme is supported by the ALS Liga België and the KU Leuven funds “Een Hart voor ALS” and “Laeversfonds voor ALS Onderzoek.” Dietmar Thal receives funds from FWO, KU Leuven, and collaborates with GE Healthcare, Janssen Pharmaceuticals, and Novartis Pharma AG. Dietmar Thal received travel reimbursement or honoraria from Novartis Pharma AD, GE Healthcare U.K., and UCB. No other potential conflict of interest relevant to this article was reported.

KEY POINTS

  • QUESTION: What is the optimal neuroinflammation target in early symptomatic ALS: TSPO or P2X7R?

  • PERTINENT FINDINGS: In this cross-sectional study on early symptomatic ALS patients, increased TSPO uptake (13%) in the MC without a regional increase in P2X7R was observed.

  • IMPLICATIONS FOR PATIENT CARE: Visualization of neuroinflammation might be used as a stratification and pharmacodynamic biomarker in therapeutic studies; therefore, optimal target determination across different disease stages is important.

Acknowledgments

We thank Kwinter Porters and Jozef Van Loock, the PET radiopharmacy and medical physics team of UZ.

Footnotes

  • Published online Sep. 27, 2019.

REFERENCES

  1. 1.↵
    1. Boillée S,
    2. Yamanaka K,
    3. Lobsiger CS,
    4. et al
    . Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389–1392.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Butovsky O,
    2. Jedrychowski MP,
    3. Moore CS,
    4. et al
    . Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131–143.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Sargsyan SA,
    2. Monk PN,
    3. Shaw PJ
    . Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia. 2005;51:241–253.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Corcia P,
    2. Tauber C,
    3. Vercoullie J,
    4. et al
    . Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7:e52941.
    OpenUrlCrossRefPubMed
  5. 5.
    1. Turner MR,
    2. Cagnin A,
    3. Turkheimer FE,
    4. et al
    . Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15:601–609.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Zürcher NR,
    2. Loggia ML,
    3. Lawson R,
    4. et al
    . Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28. Neuroimage Clin. 2015;7:409–414.
    OpenUrl
  7. 7.↵
    1. Cerami C,
    2. Iaccarino L,
    3. Perani D
    . Molecular imaging of neuroinflammation in neurodegenerative dementias: the role of in vivo PET imaging. Int J Mol Sci. 2017;18:E933.
    OpenUrl
  8. 8.↵
    1. Owen DR,
    2. Howell OW,
    3. Tang SP,
    4. et al
    . Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30:1608–1618.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Ory D,
    2. Celen S,
    3. Gijsbers R,
    4. et al
    . Preclinical evaluation of a P2X7 receptor-selective radiotracer: PET studies in a rat model with local overexpression of the human P2X7 receptor and in nonhuman primates. J Nucl Med. 2016;57:1436–1441.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Van Weehaeghe D,
    2. Koole M,
    3. Schmidt M,
    4. et al
    . [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2019;46:2051–2064.
    OpenUrl
  11. 11.↵
    1. Brettschneider J,
    2. Del Tredici K,
    3. Toledo JB,
    4. et al
    . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20–38.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Desikan RS,
    2. Segonne F,
    3. Fischl B,
    4. et al
    . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–980.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Cieślak M,
    2. Roszek K,
    3. Wujak M
    . Purinergic implication in amyotrophic lateral sclerosis: from pathological mechanisms to therapeutic perspectives. Purinergic Signal. 2019;15:1–15.
    OpenUrl
  14. 14.↵
    1. Yiangou Y,
    2. Facer P,
    3. Durrenberger P,
    4. et al
    . COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Zhang J
    . Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. J Neuroinflammation. 2015;12:108.
    OpenUrl
  16. 16.↵
    1. Monif M,
    2. Burnstock G,
    3. Williams DA
    . Microglia: proliferation and activation driven by the P2X7 receptor. Int J Biochem Cell Biol. 2010;42:1753–1756.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Lavisse S,
    2. Inoue K,
    3. Jan C,
    4. et al
    . [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain. Eur J Nucl Med Mol Imaging. 2015;42:478–494.
    OpenUrl
  18. 18.
    1. Ory D,
    2. Postnov A,
    3. Koole M,
    4. et al
    . Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F]DPA-714 PET. Eur J Nucl Med Mol Imaging. 2016;43:163–172.
    OpenUrl
  19. 19.↵
    1. Ory D,
    2. Planas A,
    3. Dresselaers T,
    4. et al
    . PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nucl Med Biol. 2015;42:753–761.
    OpenUrlCrossRefPubMed
  • Received for publication June 3, 2019.
  • Accepted for publication August 26, 2019.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords